Clinical Trial

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months). The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-04-28; most recent amendment 2024-12-18.
Status change: Not Yet Recruiting → Recruiting 2021-07-20
Trial Details
NCT Number NCT04869436
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators: Mount Sinai Hospital, Canada
Conditions Chronic Rhinosinusitis With Nasal Polyps, Olfactory Disorder
Enrollment 27 participants
Start Date 2021-07-19
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-20